Last updated: July 30, 2026
Executive summary: CRIXIVAN (indinavir) is a legacy HIV protease inhibitor with sharply diminished global demand after the rise of boosted protease inhibitor regimens and integrase-based therapies. The product’s remaining economics are driven by residual guideline use in selected patient populations, investigator-prescribed “salvage” use, pharmacy channel dynamics for older NDCs, and the extent of ongoing payer coverage. From a patent and regulatory standpoint, CRIXIVAN is long past initial FDA approvals, with exclusivity and Orange Book protection long expired, leaving the market exposed to generic substitution and supply competition. The practical financial trajectory is therefore characterized by sustained unit erosion, price compression, and contract-dependent volumes rather than growth.
What is CRIXIVAN (indinavir) and where does it sit in HIV treatment today?
Featured answer: CRIXIVAN is indinavir, a first-generation HIV protease inhibitor. Its role in modern antiretroviral therapy is limited to niche use cases where alternative regimens are unsuitable or where clinicians select protease inhibitor–based strategies for resistance or tolerability considerations.
Key clinical placement drivers
Indinavir is used in combination antiretroviral therapy (cART). Its market positioning historically depended on:
- Protease inhibitor regimen selection in early cART eras (pre-integrase dominance)
- Resistance management in patients with prior exposure to other classes
- Access to protease inhibitor options when integrase inhibitors were not used or were contraindicated
Why demand declined
The major market dynamics behind declining utilization are structural:
- Integrase strand transfer inhibitors (INSTIs) displaced protease inhibitors in first-line regimens due to efficacy and tolerability
- Boosting strategies with ritonavir improved protease inhibitor potency and convenience, changing regimen preference
- Pill burden, food requirements, tolerability, and long-term adverse effects reduced prescriber pull versus newer agents
How has CRIXIVAN revenue trended over time and what explains the financial trajectory?
Featured answer: CRIXIVAN has moved from meaningful legacy revenue in the early protease inhibitor era to a low-volume, price-compressed commodity-like segment dominated by generic availability and payer substitution.
Revenue shape consistent with legacy HIV assets
Legacy antiretrovirals typically follow a pattern:
- High adoption during class buildout (protease inhibitor growth)
- Peak or plateau as cART standardizes
- Sustained decline after category shifts (INSTIs, once-daily options, improved safety)
- Remaining revenue tied to residual demand and channel inertia (older patients, pharmacy contracts)
Financial drivers that still matter
Even for long-established assets, the remaining revenue base is sensitive to:
- Reimbursement and formulary status (preferred vs non-preferred placement)
- Generic ASP compression in overlapping generics
- Package/NDC availability (inventory cycles that temporarily lift or depress sales)
- Patient churn (switching to newer regimens)
What patents protect CRIXIVAN (indinavir) and when did the patent estate expire?
Featured answer: The CRIXIVAN patent estate and exclusivity protections for indinavir products are effectively exhausted for practical market authorization, leaving generic manufacturers free to compete on availability and pricing.
Practical implication for market economics
With exclusivity expired:
- Price competition accelerates
- Contract pharmacy ordering becomes the primary determinant of volume
- Brand value shifts to supply reliability and legacy prescriber comfort, not regulatory exclusivity
Patent-to-market linkage (how the estate affects revenue)
For legacy generics-exposed assets, patent expiration typically triggers:
- Entry of multiple generic manufacturers
- ASP and gross-to-net compression from rebates and contracting
- Reduced promotional spend and smaller payer-specific differentiation
(This section summarizes the market consequence of an exhausted exclusivity regime rather than listing specific Orange Book patents because the request centers on market dynamics and financial trajectory.)
What is the Orange Book status of CRIXIVAN and how does that affect generic entry risk?
Featured answer: CRIXIVAN is not positioned as an exclusivity-protected product in the current era. The generic entry risk is not about “if” but about “which” competitors can supply and win contracts for older NDCs.
How Orange Book status translates into commercial risk
When Orange Book listings tied to brand exclusivity are expired:
- FDA authorization is less constrained by regulatory patent thickets
- Competitive entry becomes a logistics and contracting contest
- Litigation leverage falls unless new formulation or method patents exist (rare for a legacy molecule)
Which generic companies supply indinavir and how does multi-source competition shape pricing?
Featured answer: CRIXIVAN’s market is characterized by generic indinavir multi-source availability, which drives ASP compression and makes revenue largely contract-driven.
Multi-source competition mechanisms
- Wholesale channel substitution reduces brand pull-through
- Managed care step therapy pressures remaining brand placements
- Tender and rebate structures shift share to lowest net-cost suppliers
- Switching inertia keeps some patients on older regimens, but that cohort shrinks over time
Pricing and margin pattern
- Branded net sales typically fall below meaningful thresholds once generics gain broad placement
- Generic margins depend on volume scale and procurement efficiency
- Supply constraints can temporarily lift price, but that is cyclical rather than durable
What patent litigation affected CRIXIVAN or indinavir generics (and does it change the outlook)?
Featured answer: For a legacy HIV molecule with long-expired exclusivity, litigation is not the dominant forward-looking driver of market dynamics.
Forward-looking interpretation for business decisions
- The binding constraint is current multi-source availability and payer coverage, not outstanding patent barriers
- New litigation typically arises only if there are still-relevant formulation, method, or packaging patents. For indinavir’s maturity, that is not the primary commercial lever
When do HIV therapy guidelines make CRIXIVAN less likely to be used, and how does that impact volumes?
Featured answer: Guideline evolution away from protease inhibitor–based regimens in favor of INSTI-based strategies mechanically reduces the addressable population for indinavir.
Guideline-driven volume erosion
Demand is affected by:
- First-line regimen preferences
- Recommendations for simplification and tolerability
- Resistance testing algorithms that favor newer classes
Retention of niche use cases
Indinavir may persist in limited settings:
- Salvage regimens where resistance patterns favor a protease inhibitor approach
- Patients who have historical tolerability or regimen continuity needs
- Regional formulary constraints
How does CRIXIVAN compare with boosted protease inhibitors and INSTI-based therapies in competitive dynamics?
Featured answer: Indinavir faces competitive displacement from two directions: boosted protease inhibitor regimens and INSTI-based combinations with superior convenience and tolerability.
Competitive comparison (commercial lens)
- Boosted protease inhibitors: higher efficacy per regimen anchor and stronger positioning in selected salvage contexts
- INSTI regimens: category-wide preference in guidelines reduces protease inhibitor incumbency
What this means for CRIXIVAN financial trajectory
Even when prescribers retain a protease inhibitor pathway, the selection trend favors better-tolerated and simpler regimens. That compresses CRIXIVAN’s remaining utilization into a narrowing cohort.
What formulations are protected by patents for CRIXIVAN, and do they create meaningful barriers?
Featured answer: For a legacy indinavir product, formulation-level patent barriers typically do not create durable commercial insulation in the modern market.
Practical barrier categories
- Solid oral dose form IP: usually exhausted
- Coating, polymorph, stability: rarely drives long-term exclusivity decades after origin
- Process patents: may have limited effect if generic bioequivalence is already established
Business interpretation
For CRIXIVAN, the most material “barriers” are non-IP:
- Drug supply reliability
- Contracting placement
- Inventory availability for specific pack sizes/NDCs
How do FDA pathway details for CRIXIVAN influence current market supply?
Featured answer: The FDA status supports ongoing generic market authorization for a legacy molecule, making the primary supply constraint commercial rather than regulatory.
What matters operationally now
- ANDA market participation and manufacturing continuity
- Quality control, stability, and distribution coverage
- Distribution center reliability and pack-size availability
What generic entry scenarios could still affect CRIXIVAN pricing and revenue?
Featured answer: Remaining financial swing factors are mostly incremental:
- A new generic entrant can pressure net price if it wins large contracts
- A supply interruption can temporarily raise net pricing
- Formulary reversals can shift volumes quickly, even without new entry
Scenario mapping
| Scenario |
Time horizon |
Likely impact on net sales |
Key driver |
| Broad generic price undercut |
Near-term |
Down |
Contract renegotiation, ASP compression |
| Supply tightness or manufacturing outage |
Near-term to medium-term |
Up then down |
Inventory cycles |
| Formulary exclusion for residual brand use |
Medium-term |
Down |
Managed care changes |
| NDC discontinuations then reorders |
Medium-term |
Volatile |
Package availability |
Key takeaways
- CRIXIVAN’s financial trajectory is dominated by legacy displacement: INSTI-based therapy preference and protease inhibitor optimization reduced the addressable patient population.
- With exclusivity long expired, the market is exposed to generic multi-source competition, driving pricing toward net-cost contracting and volume-driven economics.
- Forward-looking financial performance depends more on formulary placement, NDC/package supply, and contracting than on patent leverage or regulatory barriers.
- Remaining use is niche and eroding via guideline-driven switching and patient churn, limiting durable revenue upside.
FAQs
-
Why is indinavir less prescribed than newer HIV drugs?
INSTI-based regimens displaced protease inhibitors due to improved efficacy, convenience, and tolerability profiles, shrinking the eligible population for indinavir anchor regimens.
-
Does CRIXIVAN face biosimilar competition?
No. CRIXIVAN is a small-molecule drug; biosimilar frameworks apply to biologics, not indinavir.
-
What drives short-term fluctuations in CRIXIVAN sales?
Contracting and pharmacy channel ordering based on NDC availability, supply continuity, and rebate structures.
-
What is the main threat to remaining CRIXIVAN revenue?
Continued generic penetration and formulary substitution that shifts remaining volume to lower net-cost suppliers.
-
Could patent litigation still impact indinavir pricing?
Not typically in a legacy, long-expired exclusivity context. Competitive outcomes are more sensitive to supply and managed care contracting than to active patent barriers.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (CRIXIVAN/indinavir listings). FDA.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services (DHHS).
- World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. WHO.
